Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
The goal, wrote Francoise Barré-Sinoussi in 1983 on her lab book page, was "to find an activity of reverse transcriptase type HTLV in the culture supernatants." Barré-Sinoussi, in her mid-30s at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results